A study published in JAMA Network Open has uncovered disturbing trends in mental health treatment following cannabis legalisation, raising serious concerns about the broader psychological impact of liberalised cannabis policies. While advocates have celebrated decreased benzodiazepine prescriptions, a careful analysis of the data reveals a more complex and potentially alarming picture of deteriorating mental health outcomes in states with legalised cannabis.

The Study: Scope and Methodology

The research, unprecedented in its scale, examined 9,438,716 commercially insured patients across multiple states, tracking prescription patterns for five major classes of psychotropic medications between 2007 and 2020. Using sophisticated synthetic control methods, researchers analysed how both medical and recreational cannabis laws affected prescription patterns for benzodiazepines, antidepressants, antipsychotics, barbiturates, and sleep medications.

Troubling Trends in Mental Health Treatment

Rising Antidepressant Use

The data reveals a striking pattern of increased antidepressant use following cannabis legalisation:

• Medical cannabis law implementation was associated with a 3.8% increase in antidepressant fills per 10,000 enrollees
• Medical dispensary openings corresponded with an even more dramatic 8.8% increase
• These increases showed minimal state-to-state variation, suggesting a consistent pattern rather than isolated incidents

Concerning Spike in Antipsychotic Medications

Perhaps most alarming are the findings regarding antipsychotic medication use:

• Both medical cannabis law implementation and dispensary openings were associated with a 2.5% increase in the mean number of antipsychotic prescription fills per patient
• Medical dispensary openings correlated with a 2.6% increase in the mean days’ supply per prescription fill
• No states with significant results showed decreases in antipsychotic medication use

The Benzodiazepine Narrative: A Closer Look

While cannabis advocates often highlight the study’s finding of reduced benzodiazepine prescriptions (12.4% reduction after medical cannabis laws and 15.2% after recreational laws), several crucial caveats must be considered:

Methodological Limitations

1. The study’s cross-sectional design cannot establish direct causation
2. There is no evidence that individuals actually substituted cannabis for benzodiazepines
3. The research cannot account for potential concurrent use of cannabis and benzodiazepines
4. The study only examined commercially insured patients, potentially missing crucial demographic segments

Population Health Implications

The decreased benzodiazepine prescriptions, while potentially positive in isolation, must be weighed against:

• Increased use of other psychiatric medications
• Potential undertreatment of anxiety disorders
• Unknown long-term effects of cannabis as an anxiety treatment
• Possible delay in seeking proper medical intervention

Mental Health and Cannabis: A Growing Body of Concern

Psychosis Risk

The study’s findings align with mounting evidence linking cannabis use to serious mental health concerns:

• Early onset of psychosis
• Increased risk of acute psychotic episodes
• Exacerbation of existing psychotic disorders
• Potential triggering of underlying psychiatric conditions

Depression and Anxiety

The increased antidepressant prescriptions suggest potential negative effects on mood disorders:

• Possible cannabis-induced depression
• Anxiety disorders potentially masked by cannabis use
• Complications in treating co-occurring mental health conditions
• Delayed recognition of underlying mental health issues

Public Health and Policy Implications

Healthcare System Impact

The study suggests significant shifts in mental health treatment patterns:

• Increased burden on mental health services
• Higher costs associated with antipsychotic and antidepressant medications
• Potential complications in treatment planning
• Need for enhanced mental health monitoring in states with legal cannabis

Policy Considerations

These findings raise important questions for policymakers:

1. Need for more robust mental health monitoring in states with legal cannabis
2. Importance of integrating mental health screening into cannabis dispensary regulations
3. Potential necessity for mental health warnings on cannabis products
4. Requirements for mental health education in cannabis dispensaries

Research Limitations and Future Directions

Study Constraints

Several important limitations must be considered:

• Inability to track individual patient behaviors
• Limited to commercially insured population
• Potential influence of concurrent policy changes
• Variable implementation of cannabis laws across states
• Lack of data on cannabis consumption patterns

Areas for Further Research

The findings highlight crucial areas requiring additional investigation:

1. Long-term mental health outcomes in cannabis-legal states
2. Impact on specific demographic groups and vulnerable populations
3. Relationship between cannabis potency and mental health effects
4. Role of different cannabis consumption methods in mental health outcomes
5. Effectiveness of various policy interventions in mitigating mental health risks

This comprehensive study suggests that cannabis legalisation may be associated with broader negative mental health impacts than previously recognised. While decreased benzodiazepine use might offer certain benefits, the concurrent increases in antidepressant and antipsychotic medication use paint a concerning picture of population-level mental health effects.

Key Takeaways

1. Cannabis legalisation correlates with increased use of serious psychiatric medications
2. Mental health impacts appear to be more negative than positive overall
3. Current policy frameworks may inadequately address mental health risks
4. More comprehensive monitoring and intervention strategies are needed

Moving Forward

The findings underscore the need for:

• More rigorous mental health monitoring in cannabis-legal states
• Enhanced screening for mental health conditions among cannabis users
• Development of targeted interventions for at-risk populations
• Careful reconsideration of cannabis policy frameworks
• Additional research into long-term mental health impacts

As more states consider cannabis legalisation, these findings suggest the need for a more cautious, mental health-focused approach to policy development and implementation. The potential mental health consequences of cannabis legalisation may be more serious and far-reaching than previously understood, demanding careful consideration from policymakers, healthcare providers, and public health officials.

Source

Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders | Health Policy | JAMA Network Open | JAMA Network